Hotter CPI Hits Stocks, but Big Pharma Defies the Slide
Eli Lilly, Merck, AbbVie, and UnitedHealth rose as markets fell on stronger inflation data, highlighting healthcare’s defensive strength.
Eli Lilly, Merck, AbbVie, and UnitedHealth rose as markets fell on stronger inflation data, highlighting healthcare’s defensive strength.
Tukysa plus two antibody drugs cut the risk of progression or death by 36% in HER2-positive metastatic breast cancer.
Vaxcyte shares surged after VAX-31 met adult Phase 3 goals versus Prevnar 20 and Capvaxive. A BLA filing is targeted for the first half of 2028.
Newly approved Lisraya could become a blockbuster. J.P. Morgan calls dermatomyositis highly attractive and sees $2B+ U.S. peak sales.
Valneva shares surge after EMA validates its Lyme disease vaccine candidate developed with Pfizer. Phase 3 trial showed over 70% efficacy.
The new treatment, given with fulvestrant with or without palbociclib, nearly quadrupled progression-free survival versus standard therapy.